Quest Laboratories IPO GMP Guidance & Subscription Status at Chanakyanipothi.com,
👉A legacy of 31 Years.
India`s Oldest Investment & IPO website.
👉Most Trusted by Investors across India.
Table of Contents
Quest Laboratories IPO Post Listing Review:
Listed at Rs. 155.10, premium of 59.90% over the issue price of Rs. 97. The listing has been below the expectations of the grey market players.
What was the last GMP of Quest Laboratories IPO?
Premium: Rs.70
Subject to Rs.62200
Check Subscription status of Quest Laboratories IPO
On 17 May 2024 @ 5.00 (Day 2)
Review: Small IPO, so oversubscription expected
NII: 72.76 T
RII: 336.09 T
Total: 204.56 T
Application: 59488
Amount wise Subscription: Rs. 1043 Crore
What is the business of Quest Laboratories?
Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations
across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark “Quest Laboratories Limited”. The company produces a variety of products, comprising ethical drugs, generic drugs, and over the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows our Company to address a wide range of medical needs and preferences among patients.
The Company holds WHO Schedule M GMP, and GLP certifications, adhering to the stringent guidelines set by the World Health Organization. Its commitment to quality is further demonstrated by the ISO 9001:2015 certification and ISO/IEC 17025:2017 accreditation. With manufacturing under one roof, the company maintains stringent quality control standards throughout the entire manufacturing process. By doing so, it ensures that its products meet the relevant quality standards before they reach the market.
The company currently has its manufacturing facility located at Plot No. 45, Sector III, Pithampur Industrial Area, Pithampur, Dhar – 454775, Madhya Pradesh, India. The total area of the facility is approximately 4,065 square meters. Its manufacturing facilities are well equipped with the required facilities including machinery, other handling equipment’s to facilitate smooth manufacturing process and easy logistics.
The company has successfully bid for government tender contracts over the past few years, collaborating with major state and central government institutions and corporations.
Get more information about the company @ https://www.questlabltd.com/
Quest Laboratories IPO Details | |
IPO opens on | 15 May 2024 |
IPO closes on | 17 May 2024 |
Issue Type | Book Built Issue IPO |
Issue Size | 4449600 Shares / Rs 43.16 Crore |
* Fresh Issue | 4449600 Shares / Rs 43.16 Crore |
* Offer for Sale | – Sh /Rs – Cr |
Market Maker Portion | 228000 Shares |
Net offer to Public | 4221600 Shares/ Rs.40.95 Crore |
Face Value per share | Rs. 10 |
Price Band | Rs.93-97 |
Employee discount | Rs. 0 per share |
Retail Lot Size | 1200 Shares |
Listing will at | NSE SME |
Shares offered in Quest Laboratories IPO | ||
Shares | Rs. (Crore) | |
QIB (50%) | 2110800 | 20.48 |
NII (15%) | 633240 | 6.14 |
RII (35%) | 1477560 | 14.33 |
Total Shares | 4221600 | 40.95 |
Retail portion will be oversubscribed by | 1231 | |
Forms | ||
How much Shares to Apply in Quest Laboratories IPO? | ||
Min Retail Application | 1200 Shares | Rs. 116400 |
Min HNI Application | 2400 Shares | Rs.232800 |
Who are the Promoters of Quest Laboratories IPO?
The promoters of the company are Mr. Anil Kumar Sabarwal and Ms. Tejaswini Sabarwal.
What are the Objects of Quest Laboratories IPO?
The Offer comprises only of a Fresh Issue of Equity shares.
The objects of the present issue of Equity Shares are:
1.Funding of capital expenditure towards purchase of plant and machinery for expansion at the existing manufacturing facility;
2.Funding working capital requirements of the company;
3.General corporate purposes;
Quest Laboratories IPO Tentative timetable | |
IPO opens on | 15 May 2024 |
IPO Closes on | 17 May 2024 |
IPO Allotment on | 21 May 2024 |
Refund Initiation | 22 May 2024 |
Credit of Shares | 22 May 2024 |
Listing on | 23 May 2024 |
Registered Office of the Company Quest Laboratories Limited Plot No. 45, Sector III Pithampur Industrial Area, Pithampur Dhar – 454775, |
Who is the Lead Manager of Quest Laboratories IPO? Shreni Shares Limited |
Who is the Registrar to IPO? Bigshare Services Pvt Ltd |
Quest Laboratories IPO Financial & Analytical Ratios | ||||
Year | Total Income | Net Profit | EPS | RoNW |
Rs.in Cr | Rs.in Crore | Rs. | % | |
2020-21 | 30.44 | 0.66 | 0.61 | 11.12 |
2021-22 | 59.54 | 4.11 | 3.81 | 41.08 |
2022-23 | 61.87 | 5.03 | 4.66 | 33.47 |
Book Value of the Share on | 31.03.2023 | Rs 13.93 | ||
BV of the Share at cap price | after the IPO | Rs. | ||
Offer Price/upper band | Rs. 97 |
Quest Laboratories IPO Key Performance indicators |
|
Price/last EPS of 22-23 | 20.81 |
Price/BV Ratio | 6.96 |
Upper price/BV after IPO | – |
How Quest Laboratories IPO compares with the Peers?
As per DRHP | FV | Total Income | PE Ratio |
Rs. | In Cr. | @ | |
Quest Laboratories | 10 | – 20.81 | |
Beta Drugs | 10 | – | 66.43 |
Alpha Laboratories | 10 | – | 15.92 |
Zenith Drugs | 10 | 14.69 | |
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Quest Laboratories IPO To the point Guidance
Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations
across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. .
Size: The net offer is of Rs. 40.94 Crore/4221600 shares. Retail portion is Rs. 14.33 crore and it can get one time subscribed with 1231 applications. Though the size of the IPO is somewhat large, looking to the investor frenzy, over subscription may not be an issue.
Financial Snapshot: The company has shown sharp rise in the profits of the year 2022-23. The topline has increased to Rs. 61.87 Crore in 2022-23 from Rs. 30.44 Crore in 2020-21 whereas net profit has increased to Rs. 5.03 crores from Rs. 66 lacs in the year 2020-21. So compared to 100% rise in the topline, the bottomline has increased by 7.62 times. This raises eyebrows. We cannot comment whether such rise will be maintained in future or not. Even after such sharp rise in the profits, the shares are offered at PE multiple of 20.81 compared to PE multiple of about 15, of Alpha laboratories & Zenith Drugs. The IPO is not so attractive.
Quicklinks
Quest Laboratories IPO GMP today details?
Quest Laboratories IPO
Quest Laboratories IPO FAQs
What is Quest Laboratories IPO?
Quest Laboratories is a SME IPO of 4449600 equity shares of the face value of Rs. 10 aggregating up to Rs.43.16 Crores. The issue is priced at Rs.93-97 per share. The minimum order quantity is 1200 Shares.
When will Quest Laboratories IPO open?
Quest Laboratories IPO opens on May 15, 2024, and closes on May 17, 2024.
What is the lot size of Quest Laboratories IPO?
Quest Laboratories IPO lot size is 1200 Shares, and the minimum amount required is Rs.116400.
How to apply for Quest Laboratories IPO?
You can apply in Quest Laboratories IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
When is Quest Laboratories IPO allotment?
The finalization of Basis of Allotment for Quest Laboratories IPO will be done on May 21, 2024, and the allotted shares will be credited to your demat account by May 22, 2024.
When is Quest Laboratories IPO listing date?
Quest Laboratories IPO listing date is May 23, 2024.